Epigenomics News and Research

RSS

Researchers discover new factors that regulate fat formation

By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders.

1 Oct 2010

Albert Einstein College of Medicine named 1 of 5 Nathan Shock Centers

Albert Einstein College of Medicine of Yeshiva University has been named one of the National Institutes of Health's (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. The select group of five centers nationwide provides leadership in the pursuit of basic research into the biology of aging. Einstein's designation includes a $3.1 million, five-year grant from the NIH's National Institute on Aging.

17 Aug 2010

ARUP announces new version of Septin 9 methylated DNA test

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced it is offering the Septin 9 methylated DNA test, a new blood-based colorectal cancer screening method. While ARUP is not the first laboratory to offer this test, this new version, developed and validated independently by ARUP, is clinically proven to detect a higher proportion of colorectal cancers than Septin 9 tests developed by other companies.

20 Jul 2010

Researchers reveal findings on restricted lineage of iPS cells

Adult cells that have been reprogrammed into induced pluripotent stem cells (iPS cells) do not completely let go of their past, perhaps limiting their ability to function as a less controversial alternative to embryonic stem cells for basic research and cell replacement therapies, according to researchers at Children's Hospital Boston, John Hopkins University and their colleagues

20 Jul 2010

NIDDK awards Albert Einstein College of Medicine $9.5M for continuation of Diabetes Research and Training Center

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) has awarded Albert Einstein College of Medicine of Yeshiva University a five-year, $9.5 million grant for the continuation of its Diabetes Research and Training Center (DRTC). The DRTC was also awarded a $632,000 supplemental grant for equipment and additional pilot and feasibility studies through the American Recovery and Reinvestment Act (ARRA), bringing total NIH support to $10,177,000.

26 May 2010

Causes and treatment options of mental disorders need to be reassessed: JAMA commentary

It is time to reassess mental disorders, recognizing that these are disorders of brain circuits likely caused by development processes, according to a commentary in the May 19 issue of JAMA, a theme issue on mental health.

19 May 2010

The emerging science of epigenetics

Human embryonic stem cells (hESCs) possess remarkable properties of self-renewal and pluripotency, the ability to become almost any kind of cell within the body. And yet they share the same genome or set of genes with lineage-committed cells, cells fated to be or do one thing.

7 May 2010

Albert Einstein College of Medicine of Yeshiva University receives funds to expand stem cell research capabilities

Albert Einstein College of Medicine of Yeshiva University has been awarded $10 million from the National Institutes of Health to expand its stem cell research capabilities. The funds will be used to create new laboratories in order to increase its already substantial base of stem cell investigators.

16 Apr 2010

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly aggressive type of brain cancer. The research may also provide a framework for development of targeted drug treatments.

16 Apr 2010

ICGC: New era of personalised medicine for cancer patients

Published online today in Nature, a paper authored by over 200 members of the International Cancer Genome Consortium describes the beginnings of a Brave New World, a new era of personalised medicine for cancer patients.

15 Apr 2010

Gene expression in prostate cancer cell more complex than ever imagined

Scientists from Sydney's Garvan Institute of Medical Research have published a paper, online today in Nature Cell Biology, describing gene expression in a prostate cancer cell: more sweeping, more targeted and more complex than we could ever have imagined, even five years ago.

24 Feb 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

HolGenTech PGA for Genome Based Economy to be presented at the Personalized Medicine World Conference

HolGenTech, a leader in Genome Computing Architecture, will demonstrate the world's first Personal Genome Assistant (PGA) for the Genome Based Economy at the inaugural event of the Personalized Medicine World Conference at the Mountain View Computer History Museum, January 19-20. Designed to automate best choices for consumers as they shop for food, nutrients, cosmetics and more, the HolGenTech PGA leverages data from genomic tests, health database services, and user preferences to equip consumers with a practical tool to optimize health and maximize prevention.

19 Jan 2010

New blood test to identify changes in DNA linked with colorectal cancer now available in the U.S.

A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated, the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths.

12 Jan 2010

Xanthohumol compound may aid in preventing prostate cancer

The natural compound xanthohumol blocks the effects of the male hormone testosterone, therefore aiding in the prevention of prostate cancer.

9 Dec 2009

Study on Helicos BioSciences' single molecule sequencing technology published

Helicos BioSciences Corporation today announced the publication of a landmark study by Dr. Bradley Bernstein of the Massachusetts General Hospital describing the use of Helicos’ single molecule sequencing technology for the performance of genome-wide, epigenomic experiments using minute amounts of nucleic acid.

4 Dec 2009

Methyl-Seq and Ultra-Deep Resequencing applications from RainDance Technologies

RainDance Technologies, Inc., a leading provider of innovative microdroplet-based solutions for human health and disease research, announced today it will extend the capabilities of its Sequence Enrichment Solution by offering Methyl-Seq and Ultra-Deep Resequencing applications.

23 Oct 2009

GenoLogics and CLC bio to provide end-to-end informatics solution for workflow management

GenoLogics and CLC bio today announced they will provide an end-to-end informatics and analysis solution, optimized for Next Generation Sequencing research that addresses both lab and data management and data analysis all within one integrated system.

19 Oct 2009

NIH awards $1.9 million grant to Pacific Biosciences

Pacific Biosciences, a private company developing a disruptive technology platform for real-time detection of biological events at single molecule resolution, today announced that it has received grants totaling more than $1.9 million from the National Institutes of Health (NIH) as part of the American Recovery & Reinvestment Act of 2009 Research and Research Infrastructure “Grand Opportunities” grants program.

8 Oct 2009

New journal on cancer biology and genetics

SAGE announces Genes & Cancer, a monthly journal edited by Dr. Prem Reddy, founder and previous Editor-in-Chief of the prestigious and highly-ranked Oncogene.

6 Oct 2009